Quick answerCytokine release syndrome with neurotoxicity. Stop the blinatumomab infusion and notify the provider; apply oxygen and give the prescribed fluid bolus. Monitor blood pressure and naming and handwriting ability.
Why this is correctBlinatumomab activates T cells against CD19-positive cells, and the cytokine surge causes fever, capillary leak hypotension, and hypoxemia, most often in the first days of the first cycle. The same therapy can cause neurotoxicity that shows up first as word-finding and naming trouble, tremor, and confusion. The label directs interrupting the infusion for severe reactions and treating per grade, while the nurse supports airway, breathing, and circulation.
Easy analogy or mental pictureThink of the drug as a match thrown into a room full of fuel (T cells and leukemia cells). The fire spreads to the whole body (fever, low BP) and smoke reaches the brain (aphasia, tremor). First take away the match, then fight the fire.
Memory hook"Fever + low BP + can't name a pen = CRS plus ICANS." Stop, support, and watch the pen test.
NCLEX decision ruleWhen a new infusion is followed by a serious systemic reaction, stop the infusion first and support ABCs; choose monitoring that tracks both the circulatory and the neurologic arms of the reaction.
Why the other choices are wrongSeptic shock from the line shares fever and hypotension, but the clean site, onset timing, and focal language loss favor CRS with neurotoxicity; pulling the line and trending line cultures would be appropriate if infection were the leading problem, and cultures can still be sent without delaying the priority actions. Anaphylaxis appears within minutes with rash, wheezing, or swelling, which are absent, so IM epinephrine and tryptase target the wrong reaction. Hypoglycemia can cause confusion and tremor, but glucose is 104 mg/dL, so glucose checks do not measure progress. Slowing the rate continues exposure to the cause while the client is in shock.
References
1DailyMed: Blinatumomab (BLINCYTO) prescribing informationBoxed warning for cytokine release syndrome and neurological toxicities; interrupt or discontinue the infusion and treat per severity